Compounds > n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea
Page last updated: 2024-09-03

n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea and Sarcoma

n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea has been researched along with Sarcoma in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Adenis, A; Chevallier, B; Chollet, P; Curé, H; Fumoleau, P; Kerbrat, P; Krakowski, I; Lentz, MA; Roché, H; Tubiana, N1

Trials

1 trial(s) available for n'-(2-chloroethyl)-n-(2-(methylsulfonyl)ethyl)-n'-nitrosourea and Sarcoma

ArticleYear
Results of a phase II trial with second-line cystemustine at 60 mg/m2 in advanced soft tissue sarcoma: a trial of the EORTC Early Clinical Studies Group.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Neutropenia; Nitrosourea Compounds; Sarcoma; Thrombocytopenia; Treatment Failure

1998